Palliative topical and systemic misonidazole with low-dose irradiation for recurrent carcinoma of the cervix uteri.
This report concerns a determinate series of 11 patients with progressive recurrent cancer of the cervix uteri, who were treated with misonidazole (1 g) applied locally for 24 hours and an oral dose of 2.9 g/m2 four hours before a single mid-plane dose of 5.00 Gy. Four of 11 (36%) remained free of disease at one year. It is suggested that this is largely a hypoxic cell cytotoxic effect and is a useful method of palliation.
D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008920:Misonidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010166:Palliative Care; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
D008920:Misonidazole